Moderna (MRNA) Q1 2026 Earnings Transcript

Moderna reported Q1 revenue of $400 million, up $300 million year over year, with a GAAP net loss of $1.3 billion versus $0.5 billion excluding an $878 million litigation settlement charge. The company reiterated 2026 revenue growth of up to 10% and full-year adjusted cash costs of about $4.2 billion, while guiding Q2 revenue to $50 million-$100 million and year-end cash to $4.5 billion-$5.0 billion. Positively, Moderna secured EU approvals for mCOMBRIAX and mNEXSPIKE, advanced multiple Phase III programs, and kept key pipeline readouts on track for 2026.

Analysis

The market is likely to over-index on the litigation headline and underweight the operating inflection: the core business is still shrinking in absolute relevance, but the cost structure is now falling faster than revenue, which improves the odds of a cleaner 2027 earnings setup if the respiratory rollout works. The real near-term swing factor is not the reported quarter; it's whether EU launches can translate into durable reimbursement and procurement contracts before the U.S. flu readout and whether that creates a credible bridge to a multi-product revenue base rather than one-off government deliveries.

The biggest second-order effect is competitive: a successful combination vaccine launch in Europe raises the bar for every legacy flu/COVID and standalone respiratory player because health systems will prefer fewer injections and simpler logistics. That said, the adoption curve is likely slower than bulls expect; pricing/reimbursement is the bottleneck, so the first 12 months are more about access wins than volume, which argues for revenue step-ups in 2027-2028 rather than immediate monetization.

On the pipeline side, the oncology program is now a capital-allocation option value story, not a commercial story. The monotherapy move into earlier-stage lung cancer is strategically smart because it broadens the addressable population and could de-risk the platform’s safety narrative, but it also creates more binary readouts clustered into 2H26-2027 that will dominate the stock’s path. If those interim signals miss, the market will quickly reprice the platform premium; if they hit, the multiple can rerate before meaningful product revenue arrives.

The contrarian view is that the settlement may actually improve the equity case by removing a persistent overhang and forcing management discipline. But the stock remains hostage to execution timing: cash burn is still material, and the company is effectively asking investors to finance multiple shots on goal for another 18-24 months. That makes this a catalyst-driven trade, not a buy-and-forget compounder.

Key Decisions for Investors

• Long MRNA into the August 5 flu PDUFA as a 3-6 month catalyst trade; upside is a cleaner respiratory franchise narrative, but size modestly because approval alone does not solve reimbursement or demand visibility.
• Buy MRNA call spreads targeting 1H27 instead of stock if positioning for EU combo-vaccine commercialization; the market is likely to undervalue the optionality until pricing/access data emerge, while downside is limited to premium paid.
• Pair trade: long MRNA / short a legacy vaccine or respiratory incumbent basket over 6-12 months if you want to express mix-shift toward fewer-injection combination products; the thesis is channel simplification and payer preference, not immediate unit volume.
• If holding MRNA common, hedge with downside puts into the 2H26 oncology readouts; the stock should react sharply to any interim failure because the platform valuation is increasingly anchored to late-stage clinical credibility.
• Avoid chasing the stock on the litigation settlement relief alone; treat any post-earnings strength as an opportunity to trim unless you have conviction on reimbursement traction in Europe or a positive U.S. flu regulatory outcome.